BDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerabilit…

Non-small Cell Lung CancerHistiocytic NeoplasmHistiocytosis+29 more

~Estimated

~$10 – $7,500

Institut de Recherches Internationales ServierNCT05786924

Phase 1

NEO-COMBAT XL: Neoadjuvant and Maintenance XL092 and Cemiplimab in BRAF V600E-wildtype Anaplastic Thyroid Cancer: a Phase 1B Study

This multicenter study examines the safety and feasibility of the combination of neoadjuvant XL092 and cemiplimab prior to surgical resection in participants w…

Anaplastic Thyroid CancerThyroid CancerBRAF Mutation-Related Tumors

~Estimated

~$10 – $6,250

UNC Lineberger Comprehensive Cancer CenterNCT06902376